Prostate cancer is the most diagnosed cancer and the second most common cause of cancer-related deaths in Australian males. Therefore, the screening, assessment, diagnosis and treatment of this disease is vital for general practitioners.
However, there has always been conflicting advice on whether a GP should order PSA (prostate specific antigen) testing for their patients, due to the ambiguity around the potential benefits and risks of the test. Since the existing guidelines were released in 2015, there have been significant advancements in technologies available to diagnose and monitor prostate cancer with better outcomes for patients.
PSA testing best-practice
Harm minimisation to reduce over-diagnosis and treatment
Why active surveillance is safe and appropriate for low grade cancers
How to support patients who are anxious on active surveillance
Join us in this webinar as we discuss the advancements in screening and assessment that can inform contemporary care in primary health settings. View the webinar here: Prostate health: advances in screening and assessment
Prostate Cancer Specialist Telenursing Service | PCFA Ph: 1800 22 00 99
Assoc Prof Jeremy Grummet is a urological surgeon with specific training and expertise in urological cancers. He is a pioneer of focal therapy for intermediate-risk localised prostate cancer, having started practising focal therapy in 2015 and is co-principal investigator on the LIBERATE focal brachytherapy clinical registry.
He also performs MRI-targeted transperineal biopsy for maximal accuracy and minimal risk in prostate cancer diagnosis. As a strong advocate of active surveillance for low-risk prostate cancer to minimise unnecessary treatment, Jeremy was a site investigator at Alfred Health on the PRIAS study, the largest worldwide study assessing outcomes for patients on active surveillance. Jeremy is an expert advisor for Healthy Male.